Cytokinetics, Inc.
Cytokinetics Announces Financing Agreements and Asset Purchase
Summary
On May 22, 2024, Cytokinetics, Incorporated announced amendments to its 2022 Development Funding Loan Agreement and Revenue Participation Right Purchase Agreement with Royalty Pharma, and entered into new agreements providing up to $325 million in additional term loans and restructuring royalty rights for its drug aficamten. Cytokinetics also entered into a new 2024 Development Funding Loan Agreement and a CK-586 Revenue Participation Right Purchase Agreement with Royalty Pharma for its drug CK-586. Additionally, Cytokinetics entered into a Stock Purchase Agreement with Royalty Pharma.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement